La cadena de opciones muestra datos clave de las opciones de acciones de Treace Medical Concepts a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Treace Medical Concepts..

Treace Medical Concepts (NASDAQ:TMCI) Bolsa, Cadena de Opciones

Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Descubre las acciones que lideran el premercado con sorprendentes subidas y caídas. INNOVATE y más protagonistas hoy.

Las acciones de INNOVATE (VATE) cotizan un 19% más alto; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts Inc

WIIM

GSAT

Globalstar shares are trading higher after the company announced it signed an agreement with SpaceX to provide satellite services for the launch of Falcon 9.

ASGN

ASGN shares are trading lower after Jefferies downgraded the stock from Hold to Underperform and cut its price target from $53 to $42.

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday.
The Dow traded down 1% to 44,379.69 while the NASDAQ declined 0.85% to 20,426.99. The S&amp;P 500 also fell, dropping, 0.39% to 6,255.16.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46270965/top-3-tech-and-telecom-stocks-that-are-set-to-fly-in-q3">Top 3 Tech And Telecom Stocks That Are Set To Fly In Q3</a>
Leading and Lagging Sectors Industrials shares jumped by 0.1% on Monday.
In trading on Monday, consumer discretionary stocks dipped by 1.1%.
Top Headline
Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) announced topline results from Part 2 of the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, showing clinically meaningful and statistically significant improvements across the primary and all key secondary endpoints.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares shot up 319% to $4.99 after the company was granted FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma.</li>
<li>Shares of Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) got a boost, surging 79% to $17.98 after the company announced preclinical efficacy with ART12.11 in a stress-induced depression model.</li>
<li>LogProstyle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGPS#NYSE">LGPS</a>) shares were also up, gaining 155% to $2.08 after the company reported a year-over-year increase in FY25 financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Core Scientific, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares dropped 21% to $14.21 after CoreWeave announced plans to acquire the company in an all-stock deal.</li>
<li>Shares of Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) were down 51% to $3.2964 after the company reported an 89% response rate in its Urticaria study and will halt the program.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) was down, falling 16% to $40.03 after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $67.44 while gold traded down 0.5% at $3,325.80.
Silver traded down 0.8% to $36.795 on Monday, while copper fell 2.7% to $5.0025.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.43%, while Spain's IBEX 35 Index rose 0.43%. London's FTSE 100 gained 0.01%, Germany's DAX 40 gained 1% and France's CAC 40 gained 0.39% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.56%, Hong Kong's Hang Seng falling 0.12%, China's Shanghai Composite gaining 0.02% and India's BSE Sensex gaining 0.01%.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46270970/jpmorgan-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">JPMorgan Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

APGE

ARTL

COGT

Core Scientific, Inc. - Class A Common Stock

CORZ

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

LGPS

MBIO

Dow Dips 1%; Mustang Bio Shares Spike Higher

Internal Promotion Signifies the Bank's Strength and Depth of Leadership
FAIRFAX, Va., July 7, 2025 /PRNewswire/ -- MainStreet Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSB#NASDAQ">MNSB</a>, MNSBP))), the Holding Company for MainStreet Bank, announced the promotion of Alex Vari to Executive Vice President and Chief Financial Officer of MainStreet Bank.

Management

MNSB

MainStreet Bancshares Announces Promotion Of Alex Vari To EVP And CFO Of MainStreet Bank

Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) has outperformed the market over the past 10 years by 2.74% on an annualized basis producing an average annual return of 14.18%. Currently, Automatic Data Processing has a market capitalization of $125.98 billion. 
Buying $100 In ADP: If an investor had bought $100 of ADP stock 10 years ago, it would be worth $377.29 today based on a price of $309.62 for ADP at the time of writing.
<h3>Automatic Data Processing's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751905813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Automatic Data Processing Stock In The Last 10 Years

BofAmerica Securities analyst Koji Ikeda maintained Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings" target="_blank" rel="noreferrer noopener">raised the price target</a> from&nbsp;$150&nbsp;to&nbsp;$175 on Monday.
The S&amp;P Dow Jones Indices announced on July 2, 2025, that software vendor Datadog was joining the S&amp;P 500, <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46248451/datadog-shares-jump-after-sp-500-addition-replacing-juniper-networks" target="_blank" rel="noreferrer noopener">effective July 9, 2025</a>. Ikeda noted the announcement was a surprise and a positive catalyst.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/05/45221686/datadog-tops-q1-estimates-raises-revenue-outlook-flags-margin-pressure" target="_blank" rel="noreferrer noopener">Datadog Tops Q1 Estimates, Raises Revenue Outlook, Flags Margin Pressure</a>
The analyst said the stock gained 15% the following day during the shorter trading session ahead of the July 4 holiday.
Ikeda expects investors to stick with it. Ikeda also named Datadog one of its top 10 U.S. ideas for the third quarter of 2025 and one of their best small and mid-cap (SMID Cap) ideas for the second half of 2025.
The analyst reiterated his long-term AI beneficiary plus durable 20%+ revenue growth and 20%+ free cash flow margin profile bull thesis.
Now that it&#8217;s going to be a part of the S&amp;P 500, Ikeda noted that investor awareness of this DevSecOps category leader will increase meaningfully.
The price target boost reflects increasing investor sentiment and the expansion of multiple infrastructure software peer groups. Ikeda noted the forecast factors in a premium to its infrastructure software peer group average, which is warranted given its revenue growth, free cash flow upside potential, and its DevSecOps category leadership.
Ikeda projected fiscal 2025 sales of $3.23 billion and EPS of $1.69.
DDOG Price Action: Datadog stock is down 1.52% at $152.79 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45755544/rising-ai-analytics-budgets-could-lift-microsoft-snowflake-datadog" target="_blank" rel="noreferrer noopener">Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog</a></li>
</ul>
Photo: MacroEcon on Shutterstock

Price Target

Reiteration

Analyst Ratings

Tech

DDOG

Datadog's S&P 500 Debut, AI Growth Spark Analyst Upgrade — Is More Upside Ahead?

Jefferies analyst David Katz maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Hold and raises the price target from $45 to $52.

Jefferies Maintains Hold on Viking Holdings, Raises Price Target to $52

Goldman Sachs analyst Will Nance maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $91 to $104.

HOOD

Goldman Sachs Maintains Buy on Robinhood Markets, Raises Price Target to $104

Goldman Sachs analyst Joe Ritchie maintains nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) with a Buy and raises the price target from $78 to $87.

Goldman Sachs Maintains Buy on nVent Electric, Raises Price Target to $87

<a href="https://truthsocial.com/@realDonaldTrump/114812856757774700">https://truthsocial.com/@realDonaldTrump/114812856757774700</a>

Macro Notification

Politics

Economics

General

President Trump Says 25% Tariff On South Korea

Jefferies analyst David Katz maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Buy and raises the price target from $24 to $29.

NCLH

Jefferies Maintains Buy on Norwegian Cruise Line, Raises Price Target to $29

Goldman Sachs analyst James Yaro maintains Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) with a Buy and raises the price target from $266 to $298.

Goldman Sachs Maintains Buy on Evercore, Raises Price Target to $298

<a href="https://truthsocial.com/@realDonaldTrump/114812854233087572">https://truthsocial.com/@realDonaldTrump/114812854233087572</a>

President Trump Says Will Impose 25% Tariff On Japan

Goldman Sachs analyst James Yaro maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral and raises the price target from $239 to $268.

COIN

Goldman Sachs Maintains Neutral on Coinbase Global, Raises Price Target to $268

Jefferies analyst David Katz maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Hold and raises the price target from $235 to $315.

Jefferies Maintains Hold on Royal Caribbean Gr, Raises Price Target to $315

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares are trading sharply higher Monday morning. The company <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0000895419/b2dcc6da-2b02-4f01-8e06-e4657e31db11.pdf">announced</a> the appointment of Gregor van Issum as its new Executive Vice President and Chief Financial Officer, effective September 1.
What To Know: Van Issum, a seasoned semiconductor executive from ams-OSRAM, will take the financial helm as the company navigates a major strategic overhaul.
The leadership change comes just one week after Wolfspeed initiated a <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46250870/why-wolfspeed-wolf-stock-is-extremely-volatile-today">pre-packaged Chapter 11 filing</a> to fortify its financial standing. The restructuring plan, supported by a majority of its lenders, is set to slash debt by approximately $4.6 billion and cut annual cash interest payments by 60%.
Investors responded favorably to the restructuring news last week, sending the company's stock soaring 170% on a weekly basis. The appointment of a new CFO is seen as a critical step in steering the silicon carbide leader toward its goal of accelerated profitability. Van Issum will succeed interim CFO Kevin Speirits, who will resume his prior role.
CEO Robert Feurle has stated the restructuring will better position Wolfspeed to meet growing market demands. With new financial leadership in place, the company remains on track to emerge from Chapter 11 by the end of the third quarter while continuing normal operations.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WOLF shares are trading higher by 106.8% to $2.44 Monday morning. The stock is also higher by some 380% over the trailing week. WOLF has a 52-week high of $25.49 and a 52-week low of $0.39.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46250870/why-wolfspeed-wolf-stock-is-extremely-volatile-today">Why Wolfspeed Stock Is Extremely Volatile Today</a>
Image: Shutterstock

WOLF

Wolfspeed (WOLF) Stock Is Exploding Higher Monday: What's Going On?

Jefferies analyst Lloyd Byrne maintains Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) with a Buy and raises the price target from $45 to $46.

Jefferies Maintains Buy on Darling Ingredients, Raises Price Target to $46

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 5 years by 10.8% on an annualized basis producing an average annual return of 25.19%. Currently, Caterpillar has a market capitalization of $187.63 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 5 years ago, it would be worth $313.02 today based on a price of $398.94 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751904913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Caterpillar 5 Years Ago Would Be Worth This Much Today

Wolfspeed shares are trading higher after the company announced it appointed  Gregor van Issum As CFO.

Shares of cloud-based cybersecurity firm CrowdStrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) are trading lower Monday following a downgrade<a href="https://www.benzinga.com/quote/CRWD/analyst-ratings"> from Piper Sandler</a>. 
What Happened: Piper Sandler analyst Rob Owens downgraded CrowdStrike from Overweight to Neutral and maintained a price target of $505, raising valuation concerns.
With CrowdStrike shares up about 47% year-to-date, the stock has reached Piper Sandler&#8217;s base and bull case target and the firm doesn&#8217;t see a near-term scenario that would cause it to meaningfully increase estimates. 
&#8220;While our overall disposition towards the company and its longer-term opportunity as a security/IT consolidator remains favorable, we do not believe investors should be adding shares at this time as upside could be limited over the short- to medium-term,&#8221; Owens wrote in a note on Sunday.
The Piper Sandler analyst noted that the revised rating is a valuation call, similar to the update that came around the <a href="https://www.benzinga.com/news/24/07/39870313/microsoft-crowdstrike-issue-caused-largest-it-outage-in-history-showing-how-much-we-depend-on-a-hand">global outage</a> las year. Although the analyst acknowledged that management has done an impressive job in rectifying the situation, Owens still believes there has been some residual impact to the business. 
With near-term metrics likely somewhat capped due to a slowing in some core categories and federal uncertainty, the Piper Sandler analyst believes there is a level of asymmetric risk in CrowdStrike shares at the current share price. 
&#8220;As we contemplate our $505 price objective, we do not expect to increase our expectations in material fashion nor increase our already group high multiple that would justify a significantly higher objective,&#8221; the analyst wrote. 
CRWD Price Action: <a href="http://benzinga.com/quote/CRWD">CrowdStrike shares</a> were down 1.70% at $505.34 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46270970/jpmorgan-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">JPMorgan Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo: Shutterstock.

Downgrades

CRWD

CrowdStrike Stock Moves Lower As Analyst Warns Near-Term Upside Could Be Limited

Legal

Press Releases

Attention Long-Term Investors of Manhattan Associates, Inc. (NASDAQ: MANH); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Treace Medical Concepts, Inc. (NASDAQ: TMCI) – Grabar Law Office is Investigating Claims on Your Behalf!

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); Manhattan Associates, Inc. (NASDAQ: MANH); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Blue Ridge Bankshares, Inc. (NYSE: BRBS); Manhattan Associates, Inc. (NASDAQ: MANH); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Maison Solutions Inc. (NASDAQ: MSS); Methode Electronics, Inc. (NYSE: MEI); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Xponential Fitness Inc. (NYSE: XPOF)

SHAREHOLDER ALERT: Morris Kandinov Investigating VIRT, NSSC, DV, and TMCI; Shareholders are Encouraged to Contact the Firm

Notice to Long-Term Shareholders of Blue Ridge Bankshares, Inc. (NYSE: BRBS); Manhattan Associates, Inc. (NASDAQ: MANH); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Manhattan Associates, Inc. (NASDAQ: MANH); Treace Medical Concepts, Inc. (NASDAQ: TMCI); Venture Global, Inc. (NYSE: VG); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); Manhattan Associates, Inc. (NASDAQ: MANH); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of MicroStrategy, Inc. (NASDAQ: MSTR); Manhattan Associates, Inc. (NASDAQ: MANH); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Maison Solutions Inc. (NASDAQ: MSS); Napco Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Office is Investigating Claims on Your Behalf

Comments

Treace Medical Concepts

Treace Medical Concepts (TMCI) Opciones

Treace Medical Concepts (NASDAQ:TMCI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL